On November 12, 2020 Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology and neuroscience, reported the presentation of new preclinical data on its VISTA antagonist antibodies at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 35th Anniversary Annual Meeting, taking place November 9-14, 2020 (Press release, Kineta, NOV 12, 2020, View Source;utm_medium=rss&utm_campaign=kineta-presents-new-preclinical-data-at-the-2020-sitc-annual-meeting-on-its-vista-antagonist-antibodies [SID1234570728]). Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, will present a poster on the new preclinical data on the company’s fully human anti-VISTA antibodies.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"VISTA is a novel immuno-oncology checkpoint that works against myeloid cells, which are a key driver of the immunosuppressive tumor microenvironment" said Thierry Guillaudeux. "I am excited to present these new data on Kineta’s fully human lead antibodies that have demonstrated strong potency and binding against VISTA and offer the potential to become an effective immunotherapy for patients with cancer".
VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.
Presentation Details:
Poster Title: Highly Potent Fully Human anti-VISTA Antibodies: A New Target Checkpoint Inhibitor against Immunosuppressive Myeloid Cells
Date/Time: Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1:00-1:30 p.m. EST
Presenter: Thierry Guillaudeux, PhD
VISTA Publications – Kineta VISTA Poster at SITC (Free SITC Whitepaper)